Millennium Management’s Pacific Biosciences PACB Stock Holding History

Millennium Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-103,500	Closed	-$1.02M	–	6524
2023 Q4	$1.02M	Sell	103,500 -311,700	-75%	-$2.55M	﹤0.01%	4156
2023 Q3	$3.47M	Buy	415,200 +315,200	+315%	+$3.6M	﹤0.01%	3060
2023 Q2	$1.33M	Sell	100,000 -101,300	-50%	-$1.23M	﹤0.01%	3813
2023 Q1	$2.33M	Buy	201,300 +101,300	+101%	+$1.01M	﹤0.01%	3289
2022 Q4	$818K	Sell	100,000 -401,000	-80%	-$3.45M	﹤0.01%	4350
2022 Q3	$2.91M	Buy	501,000 +301,000	+151%	+$1.73M	﹤0.01%	3418
2022 Q2	$884K	Hold	200,000	–	–	﹤0.01%	4486
2022 Q1	$1.82M	Buy	200,000 +140,000	+233%	+$1.61M	﹤0.01%	3978
2021 Q4	$1.23M	Buy	+60,000	New	+$1.45M	﹤0.01%	4216
2021 Q3	–	Sell	-100,000	Closed	-$3.5M	–	7118
2021 Q2	$3.5M	Hold	100,000	–	–	﹤0.01%	3242
2021 Q1	$3.33M	Sell	100,000 -100,000	-50%	-$3.5M	﹤0.01%	3027
2020 Q4	$5.19M	Buy	+200,000	New	+$3.4M	﹤0.01%	2398

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management's PACB Position: Q1 2026 in Review

Millennium Management increased its Pacific Biosciences (PACB) stake by 13% in Q1 2026, buying an estimated $980K and bringing the position to 4,892,318 shares worth $6.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2650.

Millennium Management first reported a position in PACB in Q2 2013 and has held it in 50 quarters since. The position peaked at $38.3M in Q4 2020. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Millennium Management held 4,892,318 shares of Pacific Biosciences worth $6.46M as of Q1 2026.
Millennium Management bought 547,749 Pacific Biosciences shares in Q1 2026, an estimated $980K.
Pacific Biosciences made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2650 holding.
Millennium Management first reported a position in Pacific Biosciences in Q2 2013 and has held it in 50 quarters since.
Millennium Management's Pacific Biosciences position peaked at $38.3M in Q4 2020.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.